论文部分内容阅读
目的;观察国产血脂康在调脂治疗的同时对冠心病患者纤维蛋白原、血粘度和胰岛素抵抗的影响。方法:54例冠心病伴血清总胆固醇(TC)>5.2mmol/L或低密度脂蛋白胆固醇(LDL-C)>3.12mmol/L患者口服血脂康(0,6,2次/d),治疗8周,观察治疗前、后TC、LDLIC、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)及纤维蛋白原、血粘度和胰岛素敏感性指数(ISI)变化,另选择20例正常健康者作为对照组。结果:血脂康治疗8周后,TC、LDL-C和TG水平分别下降24.6％、34.1％和17.5％,HDL-C水平升高13.4％(P均<0.05或<0.01);纤维蛋白原和不同切变率的血粘度均显著降低(P<0.05或<0.01)。血脂康治疗前胰岛素敏感指数显著低于正常对照组,而治疗后则明显升高(P<0.05)。结论;血脂康对于冠心病患者不仅能够有效调整血脂,而且还具有降低纤维蛋白原和血粘度及改善胰岛素抵抗的有益作用。
Objective To observe the effect of domestic Xuezhikang on the fibrinogen, blood viscosity and insulin resistance in patients with coronary heart disease while adjusting lipid therapy. Methods: 54 cases of coronary heart disease with serum total cholesterol (TC)> 5.2mmol / L or low density lipoprotein cholesterol (LDL-C)> 3.12mmol / L patients oral Xuezhikang (0,6,2 times / d) The changes of TC, LDL IC, HDL-C, triglyceride and fibrinogen, blood viscosity and insulin sensitivity index (ISI) before and after treatment were observed. Twenty healthy controls were selected as control group. Results: The levels of TC, LDL-C and TG decreased by 24.6%, 34.1% and 17.5%, HDL-C increased by 13.4% (all P <0.05 or <0.01) Blood viscosity at different shear rates was significantly lower (P <0.05 or <0.01). Xuezhikang insulin sensitivity index before treatment was significantly lower than the normal control group, but after treatment was significantly higher (P <0.05). Conclusion Xuezhikang not only can effectively regulate blood lipid in patients with coronary heart disease, but also has the beneficial effect of reducing fibrinogen and blood viscosity and improving insulin resistance.